1 Abbreviations used in this paper: ADCC, antibody-dependent cellmediated cytotoxicity; MBP, mannan binding protein ; SP-A, lung surfactant protein .
using a standard lodogen reaction (13) . Specific activity was 1-2 x 106 cpm/hg. MBP was also isolated from human serum (14, 15) by affinity purification on a mannan Sepharose column. Fractions containing MBP were further purified on a Superose 6 (Pharmacia Ltd ., Milton Keynes, UK) gel filtration column, equilibrated and washed with 20 mM Tris/HCI buffer, pH 7.4, containing 1 M NaCl, 1 mM EDTA, 0.01% NaN3, 0.01% Tween 20, followed by purification on a Mono Q (Pharmacia Ltd .) FPLC ion-exchange column.
SP-A (human, recombinant) was a generous gift from K.P. Schafer, Byk Gulden Pharmazeutica, Konstanz, FRG. This preparation contains a single polypeptide chain type (type Ox3), although two highly homologous polypeptides (0x2,043) may occur naturally.
Conglutinin was purified from heat-inactivated (56°C, 30 min) bovine serum by adsorption to zymosan in the presence of 10 mM CaCl2 (16) . The zymosan was washed exhaustively with 5 mM sodium barbitone/HCI, 145 mM NaCl, 10 mM CaCl2, pH 7.4, then conglutinin was eluted in the same buffer containing 10 mM EDTA in place of CaCl2 . Conglutinin was precipitated by dialysis against distilled water, dissolved in 10 mM Tris/HCl, 140 mM NaCl, 20 mM CaCl2, pH 7.4 (TBS-Ca2'), centrifuged (10,000 g, 20 min), and applied to a mannan-Sepharose column (14) . The column was washed in TBS-Ca2', then bound protein was eluted with TBS containing 10 mM EDTA. Minor contaminants were removed by ion-exchange on a Mono-Q (Pharmacia) column equilibrated in 10 mM Tris/HCI, 50 mM NaCl, 1 mM EDTA, 0.05% NaN3, pH 7,8 . The column was developed with a 50-500 mM NaCl gradient .
Proteins used were >95% pure, as assessed by SDS-PAGE in reducing conditions (17) . The polypeptide chain size of each of the four proteins is distinct by this method, and cross-contamination was not detected (Fig. 2) .
Purification of Clq-Receptor. C1gR was purified from tonsil lymphocytes by the method of Malhotra and Sim (4) .
Binding of C1gR to Ligands Immobilized on Microtiter Plates . Microtiter plate wells were coated with 100 Al ofC1q or conglutinin at 10 g,g/ml in 10 mM potassium phosphate, 5 mM EDTA, 100 Figure 1 . Ultrastructure of C1q, SP-A, conglutinin, and MBP. Clq (a) is a hexameric structure made up of six bent collagen triple helices joined to a globular domain. SP-A is essentially identical in appearance in electron microscopy to C1q (8) . MBP has a similar monomer structure, but when isolated consists of a range of oligomers mainly trimers and tetramers (c) and hexamers (13) . Conglutinin (b) is a much larger protein, consisting of four subunits each made up of a collagenous and globular region . mM KCI, pH 7.4, for 2 h at room temperature . Plates were washed in the same buffer and nonspecific binding sites were blocked with BSA (5 mg/ml in the same buffer). C1gR was isolated as described previously (4) and iodinated with 125 I in a standard iodogen reaction (13) . Specific activity was 0.5-4 x 10 6 cpm/hg . All binding assays were done in 10 mM potassium phosphate, pH 7. trol with no potential inhibitor was included . The mixture was transferred to conglutinin-coated microtiter plate wells. After incubation and washing (as above) the "S1-labeled ClqR bound in the presence or absence of competitor was measured, as above. Binding of Ligands to U937 Cells. U937 cells were grown in 50-ml culture flasks in standard conditions (18) . U937 (10' cells) were washed three times with PBS, followed by three washes with 5 mM sodium barbitone buffer containing 5% (wt/vol) glucose, pH 7.4 (buffer A). The cell pellet was suspended in 10 ml ofbuffer A. Different dilutions of potential competitors of Clq binding, namely MBP, C1q, ClgR, or conglutinin (100 pl; maximum concentration 50 pg/ml) were incubated with "'I-labeled C1q (100 pI; 1 pg/ml) for 30 min at 37°C in buffer A. The mixture was incubated with 100 pl of U937 cell suspension (105 cells) for 30 min at 37°C. Unbound ligand was separated by spinning the cell suspension through 100 pl ofdi-(n-butyl)-phthalate for 1 min at 10,000 g . Counts per minute bound to the cell pellet in the presence or absence of competitor were measured.
Binding of 125 1-labeled ClqR to EAiC3b Cells. Sheep erythrocytes bearing bound iC3b (EAiC3b) cells were prepared by classical pathway activation followed by incubation with purified factors H and I (19) . EAiC3b cells were suspended (108 cells/ml) in 5 mM sodium barbitone buffer (pH 7.4), containing 5% (wt/vol) glucose, 0.5 MM MgC12, and 0.15 mM CaC12 (buffer B). To prepare EAiC3b-conglutinin cells, EAiC3b (3 x 108 cells) were incubated with 1 00,ug of bovine conglutinin at 37°C for 30 min and then washed three times in buffer B. Different dilutions of '15 1-labeled C1gR (100 pl; maximum concentration 2 pg/ml) were incubated with 100 Al of EaiC3b or EAiC3b-conglutinin cells for 30 min at 37°C. Unbound ligand was separated by spinning the cell suspension through 100 Al of di-(n-butyl)-phthalate at 10000 g for 1 min . Counts per minute bound to the cell pellet were measured.
Results
Binding of 121 1-labeled ClqR to Ligand Immobilized on Microtiter Plates. Dose-dependent binding of 125 I-C1gR to solid-phase immobilized Clq was observed (Fig. 3 a) . As previously shown (4), this binding is saturable. Binding of the receptor was not diminished by preincubation with soluble type IV placental collagen, but was greatly reduced by constant concentrations ofsoluble Clq, conglutinin, MBP, and SP-A (Fig. 3 a) . Direct binding of the radioiodinated ClqR to immobilized conglutinin (Fig. 3 b) was confirmed and it was shown that the C1gRconglutinin interaction was inhibited in a concentration-dependent manner by preincubation of the soluble receptor with soluble unlabeled Clq, MBP, or conglutinin (Fig. 3 b) . Each of the three soluble proteins inhibited over a similar concentration range . Again soluble collagen (not shown) and BSA (Fig. 3 b) did not inhibit the interaction .
The results shown in Fig . 3 indicate that C1q, MBP, SP-A and conglutinin all bind to C1gR. Further studies (not shown) confirmed direct binding of radioiodinated C1gR to microtiter plate-bound MBP, and inhibition of C1gR-MBP interaction by Clq, conglutinin, and SP-A. The cross-inhibition of each C1gRligand interaction by each ofthe other ligands suggests Clq, MBP, SP-A, and conglutinin bind to the same site, or overlapping sites on C1gR. This is reinforced by the similarity in concentration dependence ofinhibition (Fig. 3 b) .
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Binding of 111 1-labeled-Clq to U937 Cells. Binding assays based only on the use ofproteins immobilized on microtiter plates serve as a useful indication of binding specificity, but represent a highly artificial system. Binding ofpotential ligands to intact cells bearing C1gR, a less artificial system, was therefore studied. Since the binding of monomeric Clq to ClqR is highly dependent on ionic strength (3), these tests were done at low ionic strength to maximize binding . Binding of radioiodinated C1q to U937 cells was inhibited in a concentration-dependent manner by co-incubation with soluble ClgR, MBP, or conglutinin (Fig. 4) , indicating that binding of Clq to the cells does occur via ClgR, and that MBP and conglutinin compete for the same receptor. Binding of monomeric Clq to ClqR was considerably reduced (by -74%) at physiological salt strength compared with the low salt conditions used here. This is consistent with the results of Arvieux et al. (3) .
Binding of1211-labeled ClqR to EAiC3b. A further intact cell system in which binding of ClqR to conglutinin could be examined was devised. Conglutinin is known to bind to the complement activation product iC3b (20) . Sheep erythrocytes were sensitized with antibody (A) and coated with iC3b (EAiC3b) using purified complement classical pathway components . EAiC3b were then pre-incubated with and without conglutinin, washed, and the binding of I'll-labeled ClqR was assessed (Fig. 5 ). Cells treated with conglutinin bound more ClqR than did cells lacking conglutinin (Fig. 5) . The moderate binding of radioiodinated ClqR in the absence of conglutinin reflects the presence of small amounts of Clq (used in the complement activation procedure) on these cells. This confirms the binding of ClqR to conglutinin attached in a physiologically relevant manner to iC3b. In this study we have demonstrated that binding to C1gR is a common function of four different proteins, which were not, with the exception of C1q and MBP, previously known to have strong functional similarities. Their structural similarity is, however, evident (Fig. 1) . All of these proteins contain polypeptide chains made up of a short, NH2-terminal noncollagen-like sequence, followed by a collagenous region of repeating Gly-Xaa-Yaa sequence, and a COOH-terminal end containing a recognition domain (8) . Since C1gR is known to bind to the collagenous region of C1q (3), it is likely that it binds to the collagenous segments of MBP, SP-A, and conglutinin.
The established Lgand, C1q, is a well-characterized protein that initiates activation of the classical complement pathway (2) . It also functions as an opsonin, by interaction with C1gR on phagocytec cells (6) . The soluble MBP used here occurs as a trace protein in serum (8, 14) . It has a C-type lectin domain in the COOH-terminal region of the poly-
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Multiple Ligands for C1q Receptor peptide, and binds to mannose/N-acetyl-D-glucosamine-containing structures, particularly yeast mannns, and also to mannose-rich surface polysaccharides on HIV and on virulent gram-negative bacteria (8, 21, 22 (11, 14) , and possibly also the alternative pathway (23), so in vivo its direct opsonic activity may be less significant than its role in stimulating deposition ofanother highly effective opsonin, C3. SPA is a major protein ofpulmonary surfactant . Like MBP, it contains a C-type lectin domain within the primary sequence (8) and it has been indicated that it serves as an opsonin (24) . It is thought to have a Cal+-dependent mannose/fucose specificity (8) . The "target" for its lectin activity is unknown, but our results suggest that one of its functions may be to stimulate phagocytosis of material deposited in the lung, via interaction with C1gR on lung macrophage.
Conglutinin has until recently been considered as an obscure trace bovine serum protein . It has been detected in human plasma, again at very low levels (25) . It has Cal+-dependent lectin activity ofspecificity similar to that ofMBP, and binds directly to some yeasts (8, 10, 20, 25, 26) . Its interaction with mannose-rich oligosaccharide on the complement activation fragment iC3b is well established (20) . Opsonic (antibactericidal) activity has been demonstrated for conglutinin, although this effect appears to depend on prior deposition of iC3b on bacteria (10) . Again our results suggest that the opsonic activity of conglutinin may be mediated by interaction with C1gR. Demonstration ofthe interaction ofC1q, MBP, SP-A, and conglutinin with C1gR strongly suggests a similar function for these structurally related proteins . The rodent protein RaRF (27) may be a further member of this family, both in terms ofactivity and structure . In addition to having roles as opsonins the newly identified C1gR ligands may be expected to mediate other phenomena associated with C1q-C1gR interaction .
